Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol.

Sayd S, Thirant C, El-Habr EA, Lipecka J, Dubois LG, Bogeas A, Tahiri-Jouti N, Chneiweiss H, Junier MP.

Stem Cell Rev. 2014 Feb;10(1):103-13. doi: 10.1007/s12015-013-9465-0.

PMID:
23955573
2.

Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.

Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L.

Cell Death Dis. 2015 Jan 15;6:e1601. doi: 10.1038/cddis.2014.566.

3.

Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway.

Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, Paoletta L, Dalprà L, Strazzabosco M, Lavitrano M, Giovannoni R, Bentivegna A.

PLoS One. 2017 Jan 12;12(1):e0169854. doi: 10.1371/journal.pone.0169854. eCollection 2017.

4.

Resveratrol Induced Premature Senescence Is Associated with DNA Damage Mediated SIRT1 and SIRT2 Down-Regulation.

Kilic Eren M, Kilincli A, Eren Ö.

PLoS One. 2015 Apr 29;10(4):e0124837. doi: 10.1371/journal.pone.0124837. eCollection 2015.

5.

[SIRT2, a multi-talented deacetylase].

Sayd S, Junier MP, Chneiweiss H.

Med Sci (Paris). 2014 May;30(5):532-6. doi: 10.1051/medsci/20143005016. Epub 2014 Jun 13. Review. French.

6.

Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells.

Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Kayama T, Kitanaka C.

Stem Cell Res. 2013 Jul;11(1):601-10. doi: 10.1016/j.scr.2013.04.004. Epub 2013 Apr 11.

7.

Targeting A20 decreases glioma stem cell survival and tumor growth.

Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN.

PLoS Biol. 2010 Feb 23;8(2):e1000319. doi: 10.1371/journal.pbio.1000319.

8.

Collateral damage control in cancer therapy: defining the stem identity in gliomas.

Hsieh D.

Curr Pharm Des. 2011;17(23):2370-85. Review.

PMID:
21827417
9.

Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.

Long PM, Tighe SW, Driscoll HE, Fortner KA, Viapiano MS, Jaworski DM.

J Cell Physiol. 2015 Aug;230(8):1929-43. doi: 10.1002/jcp.24927.

10.

CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.

Mao XG, Xue XY, Wang L, Zhang X, Yan M, Tu YY, Lin W, Jiang XF, Ren HG, Zhang W, Song SJ.

Neuro Oncol. 2013 Jul;15(7):865-79. doi: 10.1093/neuonc/not029. Epub 2013 May 3.

11.

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA.

Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.

12.

Suberoylanilide hydroxamic acid represses glioma stem-like cells.

Hsu CC, Chang WC, Hsu TI, Liu JJ, Yeh SH, Wang JY, Liou JP, Ko CY, Chang KY, Chuang JY.

J Biomed Sci. 2016 Nov 18;23(1):81.

13.

Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.

Zorniak M, Clark PA, Kuo JS.

J Neurosurg. 2015 Jan;122(1):69-77. doi: 10.3171/2014.9.JNS132373.

14.

Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.

Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, Varlet P, Devaux B, Soncin F, Gavard J, Junier MP, Chneiweiss H.

Stem Cells. 2012 May;30(5):845-53. doi: 10.1002/stem.1062.

15.

Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.

Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, Chu CW, Xie Q, Bian XW, Rich JN, Bao S.

Oncotarget. 2015 Nov 10;6(35):37300-15. doi: 10.18632/oncotarget.5836.

16.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

17.

MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.

Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T, Brodie C.

Oncotarget. 2013 May;4(5):665-76.

18.
19.

SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.

Ma L, Maruwge W, Strambi A, D'Arcy P, Pellegrini P, Kis L, de Milito A, Lain S, Brodin B.

Cell Death Dis. 2014 Oct 23;5:e1483. doi: 10.1038/cddis.2014.385.

20.

Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.

Li H, Liu Y, Jiao Y, Guo A, Xu X, Qu X, Wang S, Zhao J, Li Y, Cao Y.

Oncol Rep. 2016 Jan;35(1):343-51. doi: 10.3892/or.2015.4346. Epub 2015 Oct 23.

PMID:
26498391

Supplemental Content

Support Center